BioSig Technologies (NASDAQ:BSGM – Get Free Report) had its target price cut by equities research analysts at Ascendiant Capital Markets from $2.75 to $2.50 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target points to a potential upside of 320.17% from the company’s previous close.
BioSig Technologies Price Performance
BSGM opened at $0.60 on Monday. The business’s fifty day simple moving average is $0.71 and its 200-day simple moving average is $1.06. BioSig Technologies has a 12-month low of $0.20 and a 12-month high of $2.57.
Institutional Trading of BioSig Technologies
A number of hedge funds have recently bought and sold shares of the stock. Integrity Wealth Advisors Inc. purchased a new stake in shares of BioSig Technologies during the 4th quarter worth $61,000. Geode Capital Management LLC purchased a new stake in shares of BioSig Technologies during the fourth quarter valued at about $143,000. PFG Investments LLC bought a new stake in shares of BioSig Technologies in the 4th quarter valued at about $164,000. Millennium Management LLC purchased a new position in shares of BioSig Technologies in the 4th quarter worth approximately $228,000. Finally, Legacy Investment Solutions LLC bought a new position in shares of BioSig Technologies during the 4th quarter worth approximately $5,369,000. Hedge funds and other institutional investors own 7.16% of the company’s stock.
About BioSig Technologies
BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.
Further Reading
- Five stocks we like better than BioSig Technologies
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- This Volatile Market is Made For Nickel and Diming These Names
- Canadian Penny Stocks: Can They Make You Rich?
- Gold is Making All-Time Highs, But So is This Quiet Metal
- What Are Dividends? Buy the Best Dividend Stocks
- D-Wave Quantum Slides on Chip News: Opportunity to Buy?
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
